Fig. 4.

In vivo blood glucose levels and insulin during OGTT and in vitro insulin secretion in HFD mice with and without rosuvastatin.

(A) Blood glucose and (B) insulin at study week 8 in HFD mice with and without rosuvastatin for 4 weeks. Data presented as mean ± SEM of N = 9–13 mice (C–D). As in A–B, but at study week 12. Data presented as mean ± SEM of N = 9–14 mice (E). Insulin secretion and (F) insulin content in isolated islets from mice on HFD with and without rosuvastatin. Islets were incubated for 1 h in 1 mM, 5.6 mM, 11.1 mM and 16.7 mM glucose in the absence or presence of 50 mM K⁺ or 100 nM GLP-1 as indicated. (G) Insulin secretion per insulin content from data in E–F. Data are presented as mean ± SEM of N = 4 mice, *p < 0.05 HFD vs HFD_Ros on effects of rosuvastatin using 2-way ANOVA.